With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...

After high-profile moves by Eli Lilly and other Big Pharmas to pause their U.K. | The company is looking to work out an ...

Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.

Takeda has started a workforce reduction in the U.S. as the company aims to save more than 200 billion Japanese yen ($1.26 billion) in annual costs. | Takeda has started a workforce reduction in the U ...

After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...

After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market. | ...

High-flying Samsung Biologics is facing a rare bit of public turbulence after the CDMO’s labor union secured the votes needed to strike, signaling a potential escalation in an impasse over what the | ...

Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...

With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit.  | Rocket ...

There’s no need to dive fast and furious into every single wellness trend, according to a Ludacris-fronted campaign from ...

Addressing pressing questions about upcoming ATTR-CM competition and market opportunity, Alnylam management on Tuesday ...

Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to ...